BR0312922A - Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição - Google Patents

Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição

Info

Publication number
BR0312922A
BR0312922A BR0312922-5A BR0312922A BR0312922A BR 0312922 A BR0312922 A BR 0312922A BR 0312922 A BR0312922 A BR 0312922A BR 0312922 A BR0312922 A BR 0312922A
Authority
BR
Brazil
Prior art keywords
composition
gestagen
androgen
composition containing
well
Prior art date
Application number
BR0312922-5A
Other languages
English (en)
Inventor
Reinhard Nubbemeyer
Ursula-Friederike Habenicht
Rolf Bohlmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10234525A external-priority patent/DE10234525A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0312922A publication Critical patent/BR0312922A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO CONTENDO UM ANDROGêNIO 11 BETA HALOGêNIO-ESTERóIDE E UM GESTAGêNIO ASSIM COMO UM CONTRACEPTIVO MASCULINO à BASE DESSA COMPOSIçãO". A presente invenção descreve uma nova composição química contendo um androgênio 11<225>-halogênio esteróide e o gestogênio da fórmula (I), uma composição farmacêutica contendo essa composição química, assim como um contraceptivo masculino à base dessa composição farmacêutica.
BR0312922-5A 2002-07-25 2003-07-25 Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição BR0312922A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10234525A DE10234525A1 (de) 2002-07-25 2002-07-25 Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
US44940003P 2003-02-25 2003-02-25
PCT/EP2003/008192 WO2004011008A1 (de) 2002-07-25 2003-07-25 ZUSAMMENSETZUNG, ENTHALTEND EIN ANDROGENES 11β-HALOGENSTEROID UND EIN GESTAGEN SOWIE MÄNNLICHES KONTRAZEPTIVUM AUF BASIS DIESER ZUSAMMENSETZUNG

Publications (1)

Publication Number Publication Date
BR0312922A true BR0312922A (pt) 2005-07-12

Family

ID=31189299

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312922-5A BR0312922A (pt) 2002-07-25 2003-07-25 Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição

Country Status (17)

Country Link
US (1) US20060100180A1 (pt)
EP (1) EP1524983B1 (pt)
JP (1) JP2006502997A (pt)
KR (1) KR20050025985A (pt)
CN (1) CN1671394A (pt)
AT (1) ATE382355T1 (pt)
AU (1) AU2003251636B2 (pt)
BR (1) BR0312922A (pt)
CA (1) CA2493207A1 (pt)
DE (1) DE50308933D1 (pt)
EC (1) ECSP055629A (pt)
ES (1) ES2299735T3 (pt)
HR (1) HRP20050173A2 (pt)
IL (1) IL166432A0 (pt)
MX (1) MXPA05001017A (pt)
PL (1) PL374317A1 (pt)
WO (1) WO2004011008A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011663A2 (de) * 2002-07-24 2004-02-05 Schering Aktiengesellschaft Mikrobiologische verfahren zur herstellung von 7alpha-substituierten 11alpha-hydroxysteroiden
DE10233723A1 (de) 2002-07-24 2004-02-12 Schering Ag Mikrobiologische Verfahren zur Herstellung von 7α-substituierten 11α-Hydroxysteroiden, daraus herstellbare 7α,17α-substituierte 11β-Halogensteroide, deren Herstellungsverfahren und Verwendung sowie pharmazeutische Präparate, die diese Verbindungen enthalten, sowie daraus herstellbare 7α-substituierte Estra-1,3,5(10)-triene
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3714965A1 (de) * 1987-04-30 1988-11-10 Schering Ag 3-methylen-4-androsten-17-one, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
RU2002124602A (ru) * 2000-02-15 2004-03-10 Шеринг Акциенгезелльшафт (De) Композиция для мужской контрацепции, включающая норэтистерон
EP1216699A1 (de) * 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
WO2004011008A1 (de) 2004-02-05
US20060100180A1 (en) 2006-05-11
AU2003251636A1 (en) 2004-02-16
HRP20050173A2 (en) 2005-04-30
ECSP055629A (es) 2005-04-18
PL374317A1 (en) 2005-10-03
CA2493207A1 (en) 2004-02-05
DE50308933D1 (de) 2008-02-14
ES2299735T3 (es) 2008-06-01
IL166432A0 (en) 2006-01-15
CN1671394A (zh) 2005-09-21
KR20050025985A (ko) 2005-03-14
EP1524983A1 (de) 2005-04-27
AU2003251636B2 (en) 2009-10-22
MXPA05001017A (es) 2005-06-08
EP1524983B1 (de) 2008-01-02
ATE382355T1 (de) 2008-01-15
JP2006502997A (ja) 2006-01-26

Similar Documents

Publication Publication Date Title
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
CY1108453T1 (el) Διαδικασια για την παρασκευη επλερενονης
ATE311204T1 (de) Estrogen-zyklodextrin komplexe-zusammensetzungen
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
HUP0200055A2 (hu) 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények
BR0009476A (pt) Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
GB0202635D0 (en) Formulation containing novel anti-inflammatory androstane derivative
CA2434187A1 (en) Androgenic 7-substituted 11-halogenated steroids
MEP38208A (en) COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
NO20031444D0 (no) 17&lt;alfa&gt;-fluoralkylsteroider, metoder for fremstilling av disse, og farmasöytiske preparater inneholdende angitte forbindelser
DE60317214D1 (de) Kristallines gamma-lacton der17beta-hydroxy-7alpha-(5&#39;-methyl-2&#39;-furyl)-pregna-4,9(11)-dien-3-one-21-carbonsäure
NO20020260L (no) 11&lt;beta&gt;-aryl-17,17-spirotiolansubstituerte steroider
AR036227A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD.
ATE328595T1 (de) Carvedilolpolymorph
ATE364619T1 (de) Tibolonformulierungen
DK1365768T3 (da) Anvendelse af ER-beta-selektive antagonister som contraception.
NO974256D0 (no) Anvendelse av anti-östrogener som befruktningshindrende midler for menn
AU2002339199A8 (en) Solvates of 3.beta., 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof
AR020778A1 (es) Glucuronidos de pregnano
NO20022712D0 (no) Umettede 14,15-syklopropanandrostaner, fremgangsmåte for deres fremstilling, og farmasöytiske preparater som inneholderdisse forbindelsene
RU2002126717A (ru) ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ [Н3]-3-ГИДРОКСИЭСТРА-1,3,5(10)-ТРИЕН-17-ОН И 17β-ЭСТРА-1,3,5(10)-ТРИЕН-3,17-ДИОЛ
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.